August 6, 2019

OmniPathology Validates New Genetic Test for Early Detection of HPV-Related Cancer


PASADENA, Calif – OmniPathology (, a physician-owned medical laboratory specializing in state-of-the-art pathology services, today announced its new FISH (fluorescence in situ hybridization) test to detect human papillomavirus (HPV) related cancer in patients. What makes the test unique is that it is more accurate than other means used to detect HPV-related changes. The test has already been used to identify patients who otherwise would go untreated.


The new OmniPathology FISH test uses advanced fluorescence microscopy and computer aided visual analysis to detect fluorescently labeled DNA probes bound to the TERC gene. The detection of acquired genetic changes such as amplification of the TERC gene, that leads to anal and oral squamous cell carcinoma in HPV positive patients, allows for closer follow-up and early treatment.  The new OmniPathology FISH test can be used for early detection for HPV-related malignant and premalignant conditions in both male and female patients, including groups the Centers for Disease Control (CDC) has identified as at risk for HPV, such as gay men, those who identify as transgender, and patients who are HIV-positive.


“The TERC FISH offered by Omni Pathology provides us with a helpful tool in the management of HPV infected patients,” said Dr. Philip Musikanth, President of Phillip Musikanth MD, Inc. “It gives us additional information so that  patients who may be at higher risk for progression to more serious disease like neoplasia are more closely monitored and screened.”


HPV is a sexually transmitted disease that has already infected 79 million Americans according to the CDC, and another 14 million are infected each year. In fact, HPV is so common that the CDC predicts that, without a vaccine, almost every person who is sexually active will become infected with HPV. Nine out of 10 cases of cervical cancer are caused by HPV. Unfortunately, most HPV-related diseases are slow to develop, and early detection is difficult (with the exception of cervical cancer screenings).


“HPV is the most common sexually transmitted virus and without early treatment it can lead to life-threatening cancers,” said Dr. Mohammad Kamal, founder and CEO of OmniPathology. “Our new FISH screening test bridges a gap in HPV diagnosis by its ability to accurately detect the progression of HPV virus into cancer in any patient. We hope that more ob/gyns and other physicians will take advantage of this breakthrough test and screen more patients so we can prevent HPV-related cancers.”


The OmniPathology FISH test for HPV-related cancer has already been shown to be highly effective. In early results, more than 10 percent of patients tested positive for the acquired genetic abnormalities; patients who would have otherwise gone untreated without early detection. The test is performed on a Pap sample obtained with a brush by a gynecologist, physician, or other medical professional. The OmniPathology HPV screening is available at a nominal cost and is covered by most health insurance plans.

July 16, 2019

Our Story


As a physician-owned laboratory, we take seriously the responsibility of patient advocacy and our commitment to precision and excellence.

Our focus on gastrointestinal and gynecological pathology allows us to dedicate our resources to developing state-of-the-art technologies that enhance the quality of our service and positions us as the single best laboratory partner for our physician clients.

We live in an age where advancements in genetic testing make the dream of personalized medicine a reality. We looked at the most common conditions in GI and GYN and chose to build our test menu to provide the best screening tools for these conditions. Our test menu includes the most advanced techniques in histology, cytology, molecular and cytogenetics. Our talented scientific team continues to work on developing new innovative options that will enhance the screening for colon, esophageal, cervical and anal cancers. 

In the fall of 2018, OmniPathology expanded its laboratory in Pasadena, California to 7200 square feet, creating a beautiful spacious work environment that emphasizes workflow within the lab and provides an atmosphere that inspires creativity. 

With growth came the need to upgrade our quality systems. During the past 12 months, Omni took the initiative to rethink its procedures and policies with a strong focus on documentation practices, training and competency assessment. We participate in numerous proficiency testing programs, offered by the College of American Pathologists, to ensure that our testing accuracy, reliability and precision are independently measured. Furthermore, under the leadership of our medical director and quality assurance expert, we established the highest standards in new test validation and built confidence through comprehensive staff training to perform these new tests.

Over the years, Omni has created a best-in-class standardized diagnostic database. This clinically oriented standardized approach sets us apart from everyone else. Our pathologists are subspecialty trained and deeply committed to our new mission and vision.

March 1, 2017

OmniPathology Introduces State Of The Art FilmArray Technology for GI and Respiratory Pathogen PCR Testing

The FilmArray Gastrointestinal Panel from BioFire Diagnostics is FDA-cleared PCR testing technology and provides an overall sensitivity and specificity of 98.5% and 99.3%, respectively. Rapid and accurate diagnostic testing for gastrointestinal pathogens may help identify which patients to isolate or cohort faster and determine if antibiotic therapy is appropriate.

For more information, click here.